Provides relative to fees collected by the Louisiana Department of Health related to the sale of therapeutic marijuana (EN +$225,000 SG RV See Note)
Summary
HB 657 amends Louisiana law governing therapeutic marijuana to require the Louisiana Department of Health (LDH) to charge an annual retail permit fee of $22,500 to each of the ten authorized retail permit holders that sell recommended marijuana for therapeutic use. The bill updates the renewal language for retail permits and ties the fee to the annual permit renewal process.
The bill also expands the information LDH must collect from each retail permit holder. Required reporting includes gross marijuana produced, detailed production costs, subcontracting information and costs, amounts of therapeutic chemicals produced, amounts paid to the licensee related to production, and the amount of therapeutic marijuana distributed to each retail permit holder during the year. These reporting requirements are intended to give the department more detailed oversight of the therapeutic marijuana market.
Impact
HB 657 directly amends R.S. 40:1046, the statute governing recommendation, production, and sale of marijuana for therapeutic use in Louisiana. It imposes a specific annual retail permit fee on the state’s authorized therapeutic marijuana retailers and requires LDH to collect more extensive production, cost, distribution, and payment data from those permit holders. The bill affects the ten licensed retail permit holders, the Louisiana Department of Health, and the state’s regulatory and revenue framework for the medical marijuana program.
Sentiment
The bill appears to have been broadly supported. It passed the House 93-0 and the Senate 35-4, indicating strong bipartisan approval with only limited opposition in the Senate. The available record does not include committee debate, but the vote totals suggest the measure was viewed as a routine regulatory and fee update rather than a highly controversial policy change.
Contention
The main points of potential contention are the new $22,500 annual fee and the expanded reporting obligations imposed on therapeutic marijuana retailers. Retail permit holders may view the fee as a significant operating cost, while the additional data collection requirements increase compliance and oversight. Any opposition likely centered on the financial burden on the limited number of licensed operators and on the scope of state monitoring of the medical marijuana market, though the recorded votes show little organized resistance.